Curis stock: Q3 results and webcast set for November 12
Published on 11/06/2026 at 22:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSCuris prepares for quarterly update
- Curis will release its third-quarter 2026 financial and operating results on November 12.
- Management plans to discuss the update during a conference call and webcast.
- Emavusertib remains the company’s central clinical development program in lymphoma and leukemia.
Curis said on Thursday, November 5, that it will release its third-quarter 2026 financial and operating results on Thursday, November 12. The biotechnology company plans to publish the figures at 4:00 p.m. Eastern Time and host a conference call and simultaneous webcast at 4:30 p.m.
The announcement was carried by BioSpace from a Curis press release. Investors will receive the company’s financial and operating figures before management’s call, leaving the webcast as the next scheduled forum for additional commentary.
Clinical pipeline remains central
Curis is developing emavusertib, an orally available IRAK4 and FLT3 inhibitor. The drug is being evaluated in the TakeAim Lymphoma Phase 1/2 study with ibrutinib for patients with relapsed or refractory primary central nervous system lymphoma.
The company is also studying emavusertib with zanubrutinib in the TakeAim CLL Phase 2 study for chronic lymphocytic leukemia. Curis said its monotherapy and combination studies in acute myeloid leukemia are substantially complete, with further development dependent on additional funding.
Curis company facts
- Company: Curis, Inc.
- ISIN: US2312694084
- Ticker: CRIS
- Home exchange: Nasdaq
- Third-quarter results: November 12, 2026, at 4:00 p.m. Eastern Time
- Conference call: November 12, 2026, at 4:30 p.m. Eastern Time
The broader U.S. market can be followed through current S&P 500 market coverage.
More news and analyses on Curis stock are available in the company topic.
